| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2587 | 2014 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 687 | 2019 |
| A decade of clinical development of PARP inhibitors in perspective J Mateo, CJ Lord, V Serra, A Tutt, J Balmaña, M Castroviejo-Bermejo, ... Annals of Oncology 30 (9), 1437-1447, 2019 | 522 | 2019 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ... Annals of Oncology 29 (5), 1203-1210, 2018 | 335 | 2018 |
| CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ... Cell reports 17 (9), 2367-2381, 2016 | 263 | 2016 |
| The BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin Y Wang, AJ Bernhardy, C Cruz, JJ Krais, J Nacson, E Nicolas, S Peri, ... Cancer research 76 (9), 2778-2790, 2016 | 232 | 2016 |
| Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav M López-Lago, H Lee, C Cruz, N Movilla, XR Bustelo Molecular and cellular biology 20 (5), 1678-1691, 2000 | 213 | 2000 |
| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 207 | 2018 |
| BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1 R Drost, KK Dhillon, H Van Der Gulden, I Van Der Heijden, I Brandsma, ... The Journal of clinical investigation 126 (8), 2903-2918, 2016 | 122 | 2016 |
| Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A … JC Soria, C Cruz, R Bahleda, JP Delord, L Horn, RS Herbst, D Spigel, ... European Journal of Cancer 49, S798-S798, 2013 | 117 | 2013 |
| First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy P Munster, M Mita, A Mahipal, J Nemunaitis, C Massard, T Mikkelsen, ... Cancer management and research, 10463-10476, 2019 | 72 | 2019 |
| Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status A Prat, C Cruz, KA Hoadley, O Díez, CM Perou, J Balmana Breast cancer research and treatment 147, 185-191, 2014 | 68 | 2014 |
| Interaction between HERC1 and M2-type pyruvate kinase FR Garcia-Gonzalo, C Cruz, P Muñoz, S Mazurek, E Eigenbrodt, ... FEBS letters 539 (1-3), 78-84, 2003 | 54 | 2003 |
| Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy C Cruz, A Llop-Guevara, JE Garber, BK Arun, JAP Fidalgo, A Lluch, ... Journal of Clinical Oncology 36 (31), 3134, 2018 | 52 | 2018 |
| HERC3 binding to and regulation by ubiquitin C Cruz, F Ventura, R Bartrons, JL Rosa FEBS letters 488 (1-2), 74-80, 2001 | 44 | 2001 |
| Phase I study of the investigational anti-guanylyl cyclase antibody–drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies K Almhanna, T Kalebic, C Cruz, JE Faris, DP Ryan, JA Jung, T Wyant, ... Clinical Cancer Research 22 (20), 5049-5057, 2016 | 32 | 2016 |
| Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation. C Cruz, A Teule, JM Caminal, I Blanco, JM Piulats Journal of Clinical Oncology: Official Journal of the American Society of …, 2011 | 28 | 2011 |
| Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics L Moreno, C Linossi, I Esteban, N Gadea, E Carrasco, S Bonache, ... Clinical and Translational Oncology 18, 981-987, 2016 | 27 | 2016 |
| Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. PN Munster, A Mahipal, JJ Nemunaitis, MM Mita, LG Paz-Ares, C Massard, ... Journal of Clinical Oncology 34 (15_suppl), 2505-2505, 2016 | 25 | 2016 |
| Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity J Gomez-Miragaya, A Diaz-Navarro, R Tonda, S Beltran, L Palomero, ... Cancer research 79 (16), 4258-4270, 2019 | 21 | 2019 |
